SCHEMBL6768581

SCHEMBL6768581

CCOCn1nnc(-c2ccc(Cl)cc2)c1-c1ccnc(Oc2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP1A2 P05177 4/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 3/20 0.43
CYP3A4 P08684 2/20 0.43
HIF1A Q16665 1/20 0.43
BRD4 O60885 2/20 0.40
CYP2C9 P11712 3/20 0.39
USP2 O75604 2/20 0.39
CASP1 P29466 2/20 0.39
CYP2C19 P33261 2/20 0.39
CASP7 P55210 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
GAA P10253 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773679 0.92 MAPK14 (0.44) MAPK14MEN1KMT2AHTTMAPT
SCHEMBL6774535 0.91 MAPT (0.57) MAPK14MAPTL3MBTL1BRD4
SCHEMBL6624696 0.90 MAPK14 (0.57) MAPK14MAPTL3MBTL1BRD4
SCHEMBL6779431 0.86 MAPK14 (0.53) MAPK14MEN1KMT2AMAPTL3MBTL1
SCHEMBL6772274 0.85 MAPK14 (0.60) MAPK14MAPTL3MBTL1BRD4
SCHEMBL6612309 0.84 MAPK14 (0.54) MAPK14MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL6775176 0.83 MAPK14 (0.66) MAPK14MAPTL3MBTL1BRD4
SCHEMBL6773269 0.82 MAPK14 (0.54) MAPK14MAPTL3MBTL1BRD4
SCHEMBL6774295 0.82 MAPK14 (0.55) MAPK14BRD4
SCHEMBL6772180 0.82 MAPK14 (0.42) MAPK14ALDH1A1BRD4GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity PROCTER & GAMBLE COMPANY, THE 2003-01-16 US claimed
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity IL4, IL1A, IL2 MAPK14 3429/4885MEN1 4685/4885KMT2A 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.